General Information and Variability Data of DT
DT ID DTD0029
Gene Name SLCO1A2
Protein Name Organic anion transporting polypeptide 1A2
Synonyms OATP-A; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; SLCO1A2; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; Solute carrier organic anion transporter family member 1A2
Gene ID
6579
UniProt ID
P46721
TCDB ID
2.A.60.1.14
DT Family Organo Anion Transporter (OAT) Family ;
Function This Na(+)-independent transporter mediates the transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids. Selectively inhibited by the naringin.
Disease(s) Atrial fibrillation [ICD-11: BC81.3]
Chronic myelogenous leukemia [ICD-11: 2A20.0]
Dry eye disease [ICD-11: 9A79]
Dyslipidaemias [ICD-11: 5C8Z]
High blood pressure [ICD-11: BA00]
Human immunodeficiency virus infection [ICD-11: 1C62.Z]
Leukemia [ICD-11: 2A60-2B33]
Medical abortion [ICD-11: JA00.1]
Ehlers-Danlos syndrome [ICD-11: LD28.1]
Genetic Polymorphisms & Epigenetic Regulations of DT
Species-, Tissue- and Disease-specific Protein Abundances of DT
Exogenous Factor Altering DT Activity
Approved Drug(s) Transported by This DT Acebutolol Drug Info Ventricular premature beats [ICD-11: BC70] Approved [1]
Atenolol Drug Info High blood pressure [ICD-11: BA00] Approved [1]
Atorvastatin Drug Info Hyperlipidaemia [ICD-11: 5C8Z] Approved [2]
Celiprolol Drug Info High blood pressure [ICD-11: BA00] Approved [3]
Chlorambucil Drug Info Chronic lymphocytic leukemia [ICD-11: 2A82.0] Approved [4]
Cholic acid Drug Info Synthesis disorders [ICD-11: 5C52.10] Approved [5]
Ciprofloxacin Drug Info Seizure [ICD-11: 8A68] Approved [1]
Darunavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [6]
Dehydroepiandrosterone sulfate Drug Info Dyspareunia [ICD-11: GA12] Approved [7]
Dinoprostone Drug Info Medical abortion [ICD-11: JA00.1] Approved [8]
Enalapril Drug Info High blood pressure [ICD-11: BA00] Approved [9]
Enoxacin Drug Info Gonorrhea [ICD-11: 1A70-1A7Z] Approved [10]
Estrone sulfate Drug Info Menopausal symptoms [ICD-11: MF32] Approved [11]
Fexofenadine Drug Info Allergic rhinitis [ICD-11: CA08.0] Approved [2]
Gatifloxacin Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [10]
Grepafloxacin Drug Info Chronic bronchitis [ICD-11: CA20.1] Approved [10]
Hydroxyurea Drug Info Chronic myelogenous leukemia [ICD-11: 2A20.0] Approved [12]
Imatinib Drug Info Gastrointestinal stromal tumor [ICD-11: 2B5B] Approved [13]
Labetalol Drug Info Hypertension [ICD-11: BA00] Approved [3]
Levofloxacin Drug Info Gram-positive & negative bacteria infections [ICD-11: 1A00-1H0Z] Approved [10]
Levothyroxine Drug Info Hypothyroidism [ICD-11: 5A00.2] Approved [14]
Lifitegrast Drug Info Dry eye disease [ICD-11: 9A79] Approved [15]
Liothyronine Drug Info Hypothyroidism [ICD-11: 5A00.2] Approved [14]
Lomefloxacin Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [10]
Methotrexate Drug Info Leukemia [ICD-11: 2A60-2B33] Approved [16]
Montelukast Drug Info Asthma [ICD-11: CA23] Approved [17]
Nadolol Drug Info High blood pressure [ICD-11: BA00] Approved [3]
Norfloxacin Drug Info Urinary tract infections [ICD-11: GC08] Approved [10]
Ouabain Drug Info Heart failure [ICD-11: BD1Z] Approved [18]
Pitavastatin Drug Info Primary hyperlipidemia and mixed dyslipidemia [ICD-11: 5C8Z] Approved [19]
Pitavastatin calcium Drug Info Dyslipidaemias [ICD-11: 5C8Z] Approved [19]
Probenecid Drug Info Hyperuricaemia [ICD-11: 5C55.Y] Approved [20]
Quinolones Drug Info Tuberculosis [ICD-11: 1B1Z] Approved [21]
Rocuronium Drug Info Muscle relaxant [ICD-11: XM31L2] Approved [22]
Rosuvastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [23]
Saquinavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [24]
Sotalol Drug Info Maintenance of normal sinus rhythm [ICD-11: BC81.3] Approved [3]
Telmisartan Drug Info High blood pressure [ICD-11: BA00] Approved [25]
Trospium chloride Drug Info Overactive bladder [ICD-11: GC50.0] Approved [26]
Clinical Trial Drug(s) Transported by This DT Atrasentan Drug Info Endothelial dysfunction [ICD-11: BE2Z] Phase 3 [27]
Glycocholic acid Drug Info Bile acid synthesis defect [ICD-11: 5C52.11] Phase 3 [28]
BQ-123 Drug Info ST-Elevation myocardial infarction [ICD-11: BA41.0] Phase 2 [28]
Talinolol Drug Info Gastrointestinal motility disorder [ICD-11: DE2Z] Phase 1 [29]
Tauroursodeoxycholate Drug Info Asthma [ICD-11: CA23] Phase 1 [5]
Withdrawn, Discontinued or Preclinical Drug(s) Transported by This DT Aminohippuric acid Drug Info Renal function tests [ICD-11: MG02] Withdrawn [30]
Rhodamine 123 Drug Info Prostate cancer [ICD-11: 2C82] Discontinued in Phase 1 [31]
TR-14035 Drug Info Multiple scierosis [ICD-11: 8A40] Discontinued in Phase 1 [32]
Sodium taurocholate Drug Info Type 2 diabetes [ICD-11: 5A11] Preclinical [5]
Urea Drug Info Dermatological disease [ICD-11: EA00-EM0Z] Preclinical [12]
Taurocholic acid Drug Info Type 2 diabetes [ICD-11: 5A11] Terminated [33]
Endogenous Substrate(s) Cholate; Luciferin; Thyroid hormones; Dehydroepiandrosterone sulfate; Tauroursodeoxycholate; Thyroxine
Endogenous Metabolites (EMs) Handled by This DT Bile acid unspecific EM Info Identified using healthy people enrolled into 12-wk weight loss intervention [34]
Drug-DT Affinity Assessed by Cell Line
Drug(s) with Drug-DT Affinity Data Bromsulphthalein Drug Info Oocytes-OATP1A2 Km = 20 microM [5]
Estrone sulfate Drug Info Human embryonic kidney cells (HEK293)-OATP1A2 Km = 13.6 microM [16]
Estrone sulfate Drug Info Human embryonic kidney cells (HEK293)-OATP1A2 Km = 16.1 microM [33]
Estrone sulfate Drug Info Oocytes-OATP1A2 Km = 9.6 microM [33]
Estrone sulfate Drug Info Oocytes-OATP1A2 Km = 59 microM [35]
Fexofenadine Drug Info Human cervical cancer cell line (Hela)-OATP1A2 Km = 6.4 microM [36]
Levofloxacin Drug Info Oocytes-OATP1A2 Km = 136 microM [10]
Levothyroxine Drug Info Oocytes-OATP1A2 Km = 8 microM [14]
Liothyronine Drug Info Oocytes-OATP1A2 Km = 6.5 microM [14]
Methotrexate Drug Info Oocytes-OATP1A2 Km = 457 microM [16]
Ouabain Drug Info Oocytes-OATP1A2 Km = 5500 microM [35]
Pitavastatin calcium Drug Info Oocytes-OATP1A2 Km = 3.4 microM [19]
Rosuvastatin Drug Info Human cervical cancer cell line (Hela)-OATP1A2 Km = 2.6 microM [23]
Saquinavir Drug Info Oocytes-OATP1A2 Km = 36.4 microM [24]
Sodium taurocholate Drug Info Oocytes-OATP1A2 Km = 60 microM [5]
Taurocholic acid Drug Info Human embryonic kidney cells (HEK293)-OATP1A2 Km = 15.9 microM [33]
Taurocholic acid Drug Info Human liver cancer cells (HepG2)-OATP1A2 Km = 64 microM [37]
Taurocholic acid Drug Info Oocytes-OATP1A2 Km = 60 microM [5]
Trospium chloride Drug Info Primary human bladder urothelium cells (HBU) Km = 34.9 microM [26]
References
1 Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010 Nov;70(5):645-55.
2 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
3 Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
4 Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol. 2004;44:137-66.
5 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
6 P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull. 2009 Sep;32(9):1588-93.
7 Membrane transporters in drug development. Nat Rev Drug Discov. 2010 Mar;9(3):215-36.
8 Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
9 Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
10 Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
11 Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. Eur J Pharm Sci. 2011 Jul 17;43(4):297-307.
12 Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
13 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
14 Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
15 Clinical Pharmacology and Biopharmaceutics review(s)
16 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
17 Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J Clin Pharmacol. 2011 May;51(5):751-60.
18 Molecular cloning and functional characterization of the mouse organic-anion-transporting polypeptide 1 (Oatp1) and mapping of the gene to chromosome X. Biochem J. 2000 Jan 1;345 Pt 1:115-20.
19 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
20 Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther. 2001 Jul;298(1):316-22.
21 The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.14)
22 Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J Pharmacol Exp Ther. 1999 Oct;291(1):147-52.
23 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
24 Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
25 Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos. 2006 Jul;34(7):1109-15.
26 Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
27 Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther. 2006 Mar;79(3):186-96.
28 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
29 Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm Res. 2009 Mar;26(3):560-7.
30 Characterization and identification of steroid sulfate transporters of human placenta. Am J Physiol Endocrinol Metab. 2003 Feb;284(2):E390-8.
31 Characterization of rhodamine-123 as a tracer dye for use in in vitro drug transport assays. PLoS One. 2012;7(3):e33253.
32 Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. Pharm Res. 2006 Nov;23(11):2646-56.
33 Identification of multiple binding sites for substrate transport in bovine organic anion transporting polypeptide 1a2. Drug Metab Dispos. 2013 Mar;41(3):602-7.
34 Determinants of postprandial plasma bile acid kinetics in human volunteers. Am J Physiol Gastrointest Liver Physiol. 2017 Oct 1;313(4):G300-G312.
35 Multispecific amphipathic substrate transport by an organic anion transporter of human liver. J Hepatol. 1996 Nov;25(5):733-8.
36 OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71.
37 Molecular and functional characterization of bile acid transport in human hepatoblastoma HepG2 cells. Hepatology. 1996 May;23(5):1053-60.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.